New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2014
08:23 EDTRGRXRegeneRx receives orphan drug designation for Thymosin beta 4
RegeneRx Biopharmaceuticals announced that it has received Orphan Drug designation from U.S. FDA’s Office of Orphan Products Development for its drug candidate, Thymosin beta 4, or Tβ4, for the treatment of Neurotrophic Keratopathy, a serious degenerative disease of the corneal epithelium. A reduction in corneal sensitivity or complete corneal anesthesia is the hallmark of this disease and is responsible for producing corneal ulceration, perforation, pain and impaired vision. The designation, for novel drugs to treat diseases with a prevalence of less than 200,000 patients in the U.S., provides seven years of extended marketing exclusivity, waiver of FDA user fees, tax credits of up to 50% of qualified clinical trial expenses, and eligibility of FDA research grants for clinical trials. "In a previous physician-sponsored clinical study with RGN-259, the drug candidate stimulated healing within 4-8 weeks in patients with NK who had non-healing corneas for a minimum of six weeks to over a year. Our clinical experience to date also indicates that RGN-259 is safe, well-tolerated, and significantly improves patient comfort,” explained J.J. Finkelstein, RegeneRx’s president & CEO.
News For RGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for RGRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use